Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease

American Journal of Cardiology

Volumn 90, Issue 6, 2002, Pages 663-665

  Obialo, Chamberlain I ^a   Ofili, Elizabeth O ^b   Mirza, Tariq ^b  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b Primary Care Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PERFUSION; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; SPIRONOLACTONE; TREATMENT FAILURE;

EID: 0037107015     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02581-X     Document Type: Article

References (14)

1. Borghi C., Boschi S., Ambrosioni E., Melandri G., Branzi A., Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 33:1993;40-45.
2. Struthers A.D. Aldosterone escape during angiotensin converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 2:1996;47-54.
3. van Vilet A., Donker A.J.M., Nauta J.J.P., Verhengt F.W.A. Spironolactone in congestive heart failure refractory to high dose loop diuretic and low dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 71:1993;21A-28A.
4. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 341:1999;709-717.
5. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:E8.
6. Vanpee D, Swine CH. Elderly heart failure patients with drug-induced serious hyperkalemia. Aging (Milano) 2000;12:315-319.
7. Schepkens H., Vanholder R., Billiouw J., Lameire N. Life-threatening hyperkelemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone an analysis of 25 cases . Am J Med. 110:2001;438-441.
8. Beck L.H. The aging kidney. Defending a delicate balance of fluid and electrolytes. Geriatrics. 55:2000;26-28. 31-32.
9. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
10. Fliser D., Franek E., Joest M., Block S., Mutschler E., Ritz E. Renal function in the elderly impact of hypertension and cardiac function . Kidney Int. 51:1997;1196-1204.
11. Bauer J.H. Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications. Drugs Aging. 3:1993;238-245.
12. Flood C., Gherondache C., Pincus G., Tait J.F., Tait S.A., Willoughby S. The metabolism and secretion of aldosterone in elderly subjects. J Clin Invest. 46:1967;961-966.
13. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 44:1993;643-653.
14. Stichtenoth D.O., Frolich J.C. Cox-2 and the kidneys. Curr Pharm Des. 6:2000;1737-1753.